Literature DB >> 25903941

Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?

Adele L Boskey1, Josephine Marino, Lyudmila Spevak, Nancy Pleshko, Stephen Doty, Erin M Carter, Cathleen L Raggio.   

Abstract

BACKGROUND: Osteogenesis imperfecta (OI) is a genetic disease characterized by skeletal fragility and deformity. There is extensive debate regarding treatment options in adults with OI. Antiresorptive treatment reduces the number of fractures in growing oim/oim mice, an animal model that reproducibly mimics the moderate-to-severe form of OI in humans. Effects of long-term treatments with antiresorptive agents, considered for treatment of older patients with OI with similar presentation (moderate-to-severe OI) are, to date, unknown. QUESTIONS/PURPOSES: Fourier transform infrared (FTIR) imaging, which produces a map of the spatial variation in chemical composition in thin sections of bone, was used to address the following questions: (1) do oim/oim mice show a sex dependence in compositional properties at 6.5 months of age; (2) is there a sex-dependent response to treatment with antiresorptive agents used in the treatment of OI in humans; and (3) are any compositional parameters in oim/oim mice corrected to wild-type (WT) values after treatment?
METHODS: FTIR imaging data were collected from femurs from four to five mice per sex per genotype per treatment. Treatments were 24 weeks of saline, alendronate, or RANK-Fc; and 12 weeks of saline+12 weeks RANK-Fc and 12 weeks of alendronate+RANK-Fc. FTIR imaging compositional parameters measured in cortical and cancellous bones were mineral-to-matrix ratio, carbonate-to-mineral ratio, crystal size/perfection, acid phosphate substitution, collagen maturity, and their respective distributions (heterogeneities). Because of the small sample size, nonparametric statistics (Mann-Whitney U- and Kruskal-Wallis tests with Bonferroni correction) were used to compare saline-treated male and female mice of different genotypes and treatment effects by sex and genotype, respectively. Statistical significance was defined as p<0.05.
RESULTS: At 6.5 months, saline-treated male cortical oim/oim bone had increased mineral-to-matrix ratio (p=0.016), increased acid phosphate substitution (p=0.032), and decreased carbonate-to-mineral ratio (p=0.016) relative to WT. Cancellous bone in male oim/oim also had increased mineral-to-matrix ratio (p=0.016) relative to male WT. Female oim/oim mouse bone composition for all cortical and cancellous bone parameters was comparable to WT (p>0.05). Only the female WT mice showed a response of mean compositional properties to treatment, increasing mineral-to-matrix after RANK-Fc treatment in cancellous bone (p=0.036) compared with saline-treated mice. Male oim/oim increased mineral-to-matrix cortical and cancellous bone heterogeneity in response to all long-term treatments except for saline+RANK-Fc (p<0.04); female oim/oim cortical mineral-to-matrix bone heterogeneity increased with ALN+RANK-Fc and all treatments increased cancellous female oim/oim bone acid phosphate substitution heterogeneity (p<0.04).
CONCLUSIONS: Both oim/oim and WT mice, which demonstrate sex-dependent differences in composition with saline treatment, showed few responses to long-term treatment with antiresorptive agents. Female WT mice appeared to be more responsive; male oim/oim mice showed more changes in compositional heterogeneity. Changes in bone composition caused by these agents may contribute to improved bone quality in oim/oim mice, because the treatments are known to reduce fracture incidence. CLINICAL RELEVANCE: The optimal drug therapy for long-term treatment of patients with moderate-to-severe OI is unknown. Based on bone compositional changes in mice, antiresorptive treatments are useful for continued treatment in OI. There is a reported sexual dimorphism in fracture incidence in adults with OI, but to date, no one has reported differences in response to pharmaceutical intervention. This study suggests that such an investigation is warranted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25903941      PMCID: PMC4488219          DOI: 10.1007/s11999-015-4268-z

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  39 in total

1.  Alpha 2(I) collagen deficient oim mice have altered biomechanical integrity, collagen content, and collagen crosslinking of their thoracic aorta.

Authors:  Brent J Pfeiffer; Craig L Franklin; Fu-hung Hsieh; Rudolf A Bank; Charlotte L Phillips
Journal:  Matrix Biol       Date:  2005-08-10       Impact factor: 11.583

2.  Skeletal muscle weakness in osteogenesis imperfecta mice.

Authors:  Bettina A Gentry; J Andries Ferreira; Amanda J McCambridge; Marybeth Brown; Charlotte L Phillips
Journal:  Matrix Biol       Date:  2010-07-06       Impact factor: 11.583

3.  Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.

Authors:  R Bargman; R Posham; A L Boskey; E DiCarlo; C Raggio; N Pleshko
Journal:  Osteoporos Int       Date:  2011-09-08       Impact factor: 4.507

4.  Structural and mechanical differences between collagen homo- and heterotrimers: relevance for the molecular origin of brittle bone disease.

Authors:  Shu-Wei Chang; Sandra J Shefelbine; Markus J Buehler
Journal:  Biophys J       Date:  2012-02-07       Impact factor: 4.033

5.  Gender-dependence of bone structure and properties in adult osteogenesis imperfecta murine model.

Authors:  Xiaomei Yao; Stephanie M Carleton; Arin D Kettle; Jennifer Melander; Charlotte L Phillips; Yong Wang
Journal:  Ann Biomed Eng       Date:  2013-03-28       Impact factor: 3.934

Review 6.  Bisphosphonate treatment for children with disabling conditions.

Authors:  Alison M Boyce; Laura L Tosi; Scott M Paul
Journal:  PM R       Date:  2013-12-22       Impact factor: 2.298

Review 7.  Bisphosphonate therapy for osteogenesis imperfecta.

Authors:  Kerry Dwan; Carrie A Phillipi; Robert D Steiner; Donald Basel
Journal:  Cochrane Database Syst Rev       Date:  2014-07-23

8.  High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice.

Authors:  Renee Bargman; Ram Posham; Adele Boskey; Erin Carter; Edward DiCarlo; Kostas Verdelis; Cathleen Raggio; Nancy Pleshko
Journal:  Pediatr Res       Date:  2012-08-27       Impact factor: 3.756

9.  Fourier transform infrared imaging of femoral neck bone: reduced heterogeneity of mineral-to-matrix and carbonate-to-phosphate and more variable crystallinity in treatment-naive fracture cases compared with fracture-free controls.

Authors:  Samuel Gourion-Arsiquaud; Lyudmilla Lukashova; Jon Power; Nigel Loveridge; Jonathan Reeve; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

10.  Current and emerging treatments for the management of osteogenesis imperfecta.

Authors:  Elena Monti; Monica Mottes; Paolo Fraschini; Piercarlo Brunelli; Antonella Forlino; Giacomo Venturi; Francesco Doro; Silvia Perlini; Paolo Cavarzere; Franco Antoniazzi
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

View more
  8 in total

1.  Finite element analysis of bone strength in osteogenesis imperfecta.

Authors:  Peter Varga; Bettina M Willie; Chris Stephan; Kenneth M Kozloff; Philippe K Zysset
Journal:  Bone       Date:  2020-01-22       Impact factor: 4.398

2.  Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.

Authors:  Marco Masci; Min Wang; Laurianne Imbert; Aileen M Barnes; Lyudmila Spevak; Lyudmila Lukashova; Yihe Huang; Yan Ma; Joan C Marini; Christina M Jacobsen; Matthew L Warman; Adele L Boskey
Journal:  Bone       Date:  2016-04-13       Impact factor: 4.398

Review 3.  Bone quality changes associated with aging and disease: a review.

Authors:  Adele L Boskey; Laurianne Imbert
Journal:  Ann N Y Acad Sci       Date:  2017-12       Impact factor: 5.691

4.  Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine.

Authors:  Brya G Matthews; Emilie Roeder; Xi Wang; Hector Leonardo Aguila; Sun-Kyeong Lee; Danka Grcevic; Ivo Kalajzic
Journal:  Bone       Date:  2017-06-07       Impact factor: 4.398

5.  Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.

Authors:  Diana Olvera; Rachel Stolzenfeld; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2018-05-07       Impact factor: 6.741

6.  PTH(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology.

Authors:  Christopher M Bartlow; Megan E Oest; Kenneth A Mann; Nicholas D Zimmerman; Bilal B Butt; Timothy A Damron
Journal:  J Orthop Res       Date:  2016-10-03       Impact factor: 3.494

7.  Impact of Genetic and Pharmacologic Inhibition of Myostatin in a Murine Model of Osteogenesis Imperfecta.

Authors:  Catherine L Omosule; Victoria L Gremminger; Ashley M Aguillard; Youngjae Jeong; Emily N Harrelson; Lawrence Miloscio; Jason Mastaitis; Ashique Rafique; Sandra Kleiner; Ferris M Pfeiffer; Anqing Zhang; Laura C Schulz; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2020-12-18       Impact factor: 6.741

8.  Dynamic structure and composition of bone investigated by nanoscale infrared spectroscopy.

Authors:  Laurianne Imbert; Samuel Gourion-Arsiquaud; Eduardo Villarreal-Ramirez; Lyudmila Spevak; Hayat Taleb; Marjolein C H van der Meulen; Richard Mendelsohn; Adele L Boskey
Journal:  PLoS One       Date:  2018-09-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.